CSL is gathering its four business units under a unified brand identity strategy (Credit: CSL company site)

CSL brings Se­qirus, Vi­for un­der par­ent um­brel­la brand in iden­ti­ty re­vamp

CSL is gath­er­ing its brands un­der the fam­i­ly name um­brel­la, re­nam­ing its vac­cine and new­ly ac­quired nephrol­o­gy spe­cial­ty busi­ness­es with the par­ent ini­tials.

CSL Se­qirus and CSL Vi­for join CSL Plas­ma and CSL Behring as the four now uni­form­ly brand­ed busi­ness units of the glob­al bio­phar­ma. The Se­qirus vac­cine di­vi­sion was formed in 2015 with the com­bi­na­tion of bioC­SL and its pur­chase of No­var­tis’ flu vac­cine busi­ness. CSL picked up Vi­for Phar­ma late last year in an $11.7 bil­lion deal for the nephrol­o­gy, iron de­fi­cien­cy and car­dio-re­nal drug de­vel­op­er.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.